Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634615 | 0.82 | FUCA1 (0.54) | FUCA1POLBRAB9ANPC1TDP1 | |
| SCHEMBL13952043 | 0.80 | TP53 (0.55) | POLBRAB9ANPC1CHRNB4CHRNA3 | |
| SCHEMBL13931017 | 0.75 | FUCA1 (0.45) | FUCA1POLBRAB9ANPC1L3MBTL1 | |
| SCHEMBL13952151 | 0.75 | FUCA1 (0.45) | FUCA1POLBRAB9ANPC1L3MBTL1 | |
| SCHEMBL13931007 | 0.73 | GPR119 (0.47) | FUCA1RAB9A | |
| SCHEMBL13931016 | 0.73 | RAB9A (0.44) | FUCA1POLBRAB9AL3MBTL1HTT | |
| SCHEMBL4254896 | 0.73 | RAB9A (0.59) | FUCA1POLBRAB9ANPC1L3MBTL1 | |
| SCHEMBL4254635 | 0.72 | RAB9A (0.47) | FUCA1POLBRAB9AL3MBTL1 | |
| SCHEMBL4254638 | 0.72 | RAB9A (0.47) | FUCA1POLBRAB9AL3MBTL1 | |
| SCHEMBL29268504 | 0.71 | RAB9A (0.60) | FUCA1POLBRAB9ANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | ALDH1A1, ABAT, ALDH18A1 | FUCA1 3074/4885POLB 1789/4885RAB9A 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.